Dapagliflozin gets PBAC nod for HFrEF
But a bid to subsidise the agent for chronic kidney disease in the wake of favourable studies has been rejected
Dapagliflozin could soon be PBS listed as a treatment for heart failure with reduced ejection fraction following a recommendation by the PBAC.
The committee says it is satisfied that the SGLT2 inhibitor, in combination with existing therapy, provides “a significant improvement in efficacy over standard care alone”.
The decision comes almost a year after the PBAC rejected the initial application for PBS listing by dapagliflozin (Forxiga) sponsor AstraZeneca.
At the time, the committee said that, although the drug had been proven effective for this indication, “its clinical place was unclear and likely to evolve”.
